3 September 2015 - Acadia Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialisation of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Nuplazid (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease.

Nuplazid is an SSIA (selective serotonin inverse agonist) preferentially targeting 5-HT2A receptors. Through this novel mechanism, Nuplazid has demonstrated significant efficacy in Parkinson’s disease psychosis (PDP) and has the potential to avoid many of the debilitating side effects of existing antipsychotics, none of which are approved for use in PDP patients. The FDA granted Nuplazid breakthrough therapy designation for PDP in 2014.

For more details, go to: http://ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-newsArticle&ID=2084988